view article

Figure 5
Protein–protein interface druggability. Druggability analysis of relevant protein–protein interfaces using FTMap. (a) FTMap-generated hotspots at the interface of interleukin-2 (PDB entry 1m47) with the interleukin-2 receptor and the small-molecule inhibitor FRB (PDB entry 1pw6; IC50 = 6 µM). Clusters 1 (red, 18 probes), 4 (blue, 12 probes) and 9 (magenta, three probes) constitute a druggable site at the interface. Moreover, clusters 1, 4 and 7 (yellow, five probes) are in close proximity to the inhibitor. (b) FTMap-generated hotspots at the interface of ZipA (PDB entry 1f46) with FtsZ and the weak small-molecule inhibitor WAC (PDB entry 1s1s). There were no strong hotspots at the interface to form a druggable site. The inhibitor is in close proximity to the low-strength clusters 5 (orange, eight probes), 10 (red, three probes) and 13 (blue, two probes). The low binding affinity of the inhibitor at the interface is consistent with the FTMap prediction of the interface not being druggable

Journal logoSTRUCTURAL
ISSN: 2059-7983
Follow Acta Cryst. D
Sign up for e-alerts
Follow Acta Cryst. on Twitter
Follow us on facebook
Sign up for RSS feeds